HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
ATLANTA, Dec. 11, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota's executive team will participate in the Guggenheim Securities 3rd Annual Boston Healthcare Conference being held at the Langham Hotel on Tuesday, December 15, 2015 in Boston, MA.
About Biota Pharmaceuticals, Inc.
Biota Pharmaceuticals is focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: These include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics currently being evaluated in the Company's ongoing Phase 2b SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase 1 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.biotapharma.com.
Biota is a registered trademark of Biota Pharmaceuticals, Inc.
CONTACT: Mark Colonnese
Executive Vice President and Chief Financial Officer
(678) 221-3352
[email protected]
Sarah McCabe
Stern Investor Relations, Inc.
(212) 362-1200
[email protected]
